Figure 1. Relationship of Symptomatic Nevirapine-Associated Hepatotoxicity and CD4 Cell Count
This graphic illustrates a 12-fold higher risk of symptomatic hepatotoxicity in women initiating nevirapine therapy who have a CD4 cell count greater than 250 cells/mm3 when compared with those with a CD4 count less than 250 cells/mm3. Similarly, men initiating nevirapine therapy who have a CD4 cell count greater than 400 cells/mm3 have a 5-fold increased risk of developing symptomatic hepatotoxicity when compared with those with a CD4 count less than 400 cells/mm3.
Data from U.S. Food and Drug Administration. FDA public health advisory for nevirapine (Viramune).